CD19 and B-cell chronic lymphocytic leukemia: Of the 11 patients who received CD19 CAR-NK cell treatment, 8 (73%) exhibited a response with 7 (64%) having a CR at a median follow-up of 13.8 months (range, 2.8-20.0), and 1 having remission of the Richter’s transformation component but had persistent CLL, and the infused CAR-NK cells expanded and persisted for at least 12 months (97).